Browse CD48

Summary
SymbolCD48
NameCD48 molecule
Aliases BLAST; mCD48; hCD48; SLAMF2; BCM1; CD48 antigen (B-cell membrane protein); BLAST1; MEM-102; B-lymphocyte act ......
Chromosomal Location1q21.3-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Lipid-anchor, GPI-anchor
Domain PF13895 Immunoglobulin domain
PF07686 Immunoglobulin V-set domain
Function

Ligand for CD2. Might facilitate interaction between activated lymphocytes. Probably involved in regulating T-cell activation.

> Gene Ontology
 
Biological Process GO:0002250 adaptive immune response
GO:0002819 regulation of adaptive immune response
GO:0050900 leukocyte migration
Molecular Function -
Cellular Component GO:0031225 anchored component of membrane
GO:0045121 membrane raft
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04650 Natural killer cell mediated cytotoxicity
Reactome R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-109582: Hemostasis
Summary
SymbolCD48
NameCD48 molecule
Aliases BLAST; mCD48; hCD48; SLAMF2; BCM1; CD48 antigen (B-cell membrane protein); BLAST1; MEM-102; B-lymphocyte act ......
Chromosomal Location1q21.3-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CD48 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CD48 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24449212Acute Myeloid LeukemiaPromote immunityHere we show that both oncogenic proteins specifically downregulate the expression of CD48, a ligand of the natural killer (NK) cell activating receptor 2B4, thereby leading to decreased killing by NK cells.
23225218Hepatocellular CarcinomaInhibit immunityThe monocytes from HCC tissues, but not from nontumoral liver, strongly express CD48 proteins; and such monocyte-induced NK cell dysfunction was markedly attenuated by blocking CD48 receptor 2B4 on NK cells, but not by blockade of NKG2D and NKp30.
Summary
SymbolCD48
NameCD48 molecule
Aliases BLAST; mCD48; hCD48; SLAMF2; BCM1; CD48 antigen (B-cell membrane protein); BLAST1; MEM-102; B-lymphocyte act ......
Chromosomal Location1q21.3-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CD48 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCD48
NameCD48 molecule
Aliases BLAST; mCD48; hCD48; SLAMF2; BCM1; CD48 antigen (B-cell membrane protein); BLAST1; MEM-102; B-lymphocyte act ......
Chromosomal Location1q21.3-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CD48 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0470.94
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3860.839
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2070.892
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5650.28
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0510.964
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.350.367
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5710.318
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8490.55
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2590.87
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.2220.483
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6310.827
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0390.86
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CD48 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCD48
NameCD48 molecule
Aliases BLAST; mCD48; hCD48; SLAMF2; BCM1; CD48 antigen (B-cell membrane protein); BLAST1; MEM-102; B-lymphocyte act ......
Chromosomal Location1q21.3-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD48. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCD48
NameCD48 molecule
Aliases BLAST; mCD48; hCD48; SLAMF2; BCM1; CD48 antigen (B-cell membrane protein); BLAST1; MEM-102; B-lymphocyte act ......
Chromosomal Location1q21.3-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD48. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD48.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCD48
NameCD48 molecule
Aliases BLAST; mCD48; hCD48; SLAMF2; BCM1; CD48 antigen (B-cell membrane protein); BLAST1; MEM-102; B-lymphocyte act ......
Chromosomal Location1q21.3-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD48. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCD48
NameCD48 molecule
Aliases BLAST; mCD48; hCD48; SLAMF2; BCM1; CD48 antigen (B-cell membrane protein); BLAST1; MEM-102; B-lymphocyte act ......
Chromosomal Location1q21.3-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CD48 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCD48
NameCD48 molecule
Aliases BLAST; mCD48; hCD48; SLAMF2; BCM1; CD48 antigen (B-cell membrane protein); BLAST1; MEM-102; B-lymphocyte act ......
Chromosomal Location1q21.3-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CD48 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCD48
NameCD48 molecule
Aliases BLAST; mCD48; hCD48; SLAMF2; BCM1; CD48 antigen (B-cell membrane protein); BLAST1; MEM-102; B-lymphocyte act ......
Chromosomal Location1q21.3-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CD48 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.